What electrophysiology tells us about Alzheimer's disease: A window into the synchronization and connectivity of brain neurons
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2020Yazar
Babiloni, ClaudioBlinowska, Katarzyna Joanna
Bonanni, Laura
Cichocki, Andrzej
De Haan, Willem
Del Percio, Claudio
Dubois, Bruno
Escudero, Javier
Fernández, Alberto
Frisoni, Giovanni Battista
Güntekin, Bahar
Hajoś, Mihály
Hampel, Harald
Ifeachor, Emmanuel C.
Kilborn, Kerry W.
Kumar, Sanjeev
Johnsen, Kristinn
Johannsson, Magnus
Jeong, Jaeseung
Lebeau, Fiona E.N.
Lizio, Roberta
Lopes da Silva, Fernando H.
Maestu, Fernando
McGeown, William Jonathan
Mckeith, Ian G.
Moretti, Davide Vito
Nobili, Flavio Mariano
Olichney, John
Onofrj, Marco
Palop, Jorge J.
Rowan, Michael
Stocchi, Fabrizio
Struzik, Zbigniew Romuald
Tanila, Heikki
Teipel, Stephan
Taylor, John-Paul
Weiergräber, Marco
Yener, Görsev
Young-Pearse, Tracy
Drinkenburg, Wilhelmus H.
Randall, Fiona
Üst veri
Tüm öğe kaydını gösterKünye
Babiloni, C., Blinowska, K. J., Bonanni, L., Cichocki, A., De Haan, W., Del Percio, C. ... Randall, F. (2020). What electrophysiology tells us about Alzheimer's disease: A window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 85, 58-73. https://dx.doi.org/10.1016/j.neurobiolaging.2019.09.008Özet
Electrophysiology provides a real-time readout of neural functions and network capability in different brain states, on temporal (fractions of milliseconds) and spatial (micro, meso, and macro) scales unmet by other methodologies. However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer's disease (AD), despite a surge in recent validated evidence. This position paper of the ISTAART Electrophysiology Professional Interest Area endorses consolidated and translational electrophysiological techniques applied to both experimental animal models of AD and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission as well as brain network dynamics, synchronization, and functional connectivity, reflecting thalamocortical and corticocortical residual capacity. Converging evidence shows relationships between abnormalities in EEG/MEG markers and cognitive deficits in groups of AD patients at different disease stages. The supporting evidence for the application of electrophysiology in AD clinical research as well as drug discovery pathways warrants an international initiative to include the use of EEG/MEG biomarkers in the main multicentric projects planned in AD patients, to produce conclusive findings challenging the present regulatory requirements and guidelines for AD studies.
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
Neurobiology of AgingCilt
85Bağlantı
https://hdl.handle.net/20.500.12511/5206https://dx.doi.org/10.1016/j.neurobiolaging.2019.09.008